Get the Stockscreener App
40.21
0.37%
-0.15
After Hours:
40.16
-0.05
-0.12%
Royalty Pharma Plc stock is traded at $40.21, with a volume of 5.15M.
It is down -0.37% in the last 24 hours and up +4.74% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$40.36
Open:
$40.45
24h Volume:
5.15M
Relative Volume:
1.41
Market Cap:
$17.18B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
17.51
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
-2.85%
1M Performance:
+4.74%
6M Performance:
+10.95%
1Y Performance:
+33.90%
1-Day Range:
$39.92
$40.58
1-Week Range:
$39.87
$41.70
52-Week Range:
$29.66
$41.70
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
40.21 | 17.24B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Aug Technicals: Will Royalty Pharma plc stock remain a Wall Street favoriteDollar Strength & High Win Rate Trade Alerts - moha.gov.vn
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com - Investing.com South Africa
Urist Marshall, evp at Royalty Pharma, sells $815k in shares - Investing.com India
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing - marketscreener.com
Liquidity Mapping Around (RPRX) Price Events - Stock Traders Daily
Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - moha.gov.vn
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug - StreetInsider
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Prime Publishers, Inc.
Royalty pharma reports record year for royalty funding market - Investing.com
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Royalty Pharma reports $4.7 billion in transactions for 2025 - StreetInsider
Inside the $10B drug-royalty boom backing new cancer and heart drugs - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235 - Yahoo Finance
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Nigeria
Royalty Pharma provides up to $500 million for TEVA vitiligo drug - StreetInsider
Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment - Nasdaq
Royalty Pharma and Teva Enter $500 Million Funding Agreement for TEV-408 Development - Intellectia AI
Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development - Nasdaq
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation - GlobeNewswire Inc.
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - The Manila Times
Teva and Royalty Pharma enter agreement to accelerate development of potential treatment for vitiligo - marketscreener.com
Drugmakers commit up to $500M to test a potential new vitiligo treatment - Stock Titan
A $500 million bet on a new vitiligo treatment aims to speed trials - Stock Titan
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - wahanariau.com
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Increases Dividend to $0.24 Per Share - MarketBeat
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi - MSN
Royalty Pharma’s Q3 2025 Earnings Call Highlights - MSN
Royalty Pharma raises quarterly dividend by 6.8% to $0.235/share - MSN
Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026 - MarketScreener
Royalty Pharma increases quarterly dividend by 6.8% to $0.235 - Investing.com India
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20. - MarketScreener
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase - Quiver Quantitative
Royalty Pharma Announces Dividend Increase - The Manila Times
Royalty Pharma plc (RPRX) Raises Quarterly Dividend 7.3% to $0.235; 2.3% Yield - StreetInsider
Moran Wealth Management LLC Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock supported by strong cash flowsInflation Watch & Stock Timing and Entry Methods - ulpravda.ru
Is Royalty Pharma plc stock affected by interest rate hikesJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - ulpravda.ru
Trade Report: How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Value Summary & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Is Royalty Pharma plc stock ready for breakoutJuly 2025 Technicals & Short-Term Swing Trade Alerts - ulpravda.ru
170,604 Shares in Royalty Pharma PLC $RPRX Bought by Hosking Partners LLP - MarketBeat
Royalty Pharma PLC $RPRX Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma stock hits 52-week high at $41.26 By Investing.com - Investing.com Nigeria
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Barchart.com
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):